Q2 2024 Intuitive Surgical Inc Earnings Call Transcript
Key Points
- Intuitive Surgical Inc (ISRG) reported a solid 17% growth in procedures for Q2 2024 compared to Q2 2023.
- The company placed 341 da Vinci systems in the quarter, including 70 da Vinci 5 systems, indicating strong demand for new technology.
- Revenue growth of 14% in the quarter was driven by solid procedure performance and strong capital placements.
- Product margins exceeded expectations due to cost reductions, fixed overhead leverage, and some one-time nonrecurring benefits.
- Adoption of digital products and services grew significantly, with the My Intuitive app expanding to nearly 14,000 surgeons.
- Multi-port procedural headwinds continued from the previous quarter, impacting overall performance.
- System utilization growth of 2% globally was lower than historical trends, reflecting the previous year's procedure strength due to patient backlog.
- Bariatric procedures in the US declined in the mid-single digit range, indicating a potential area of concern.
- Capital placements in Europe and China faced pressure due to health system budget constraints and emerging domestic robotic systems.
- The operating environment in China remains challenging due to anti-corruption initiatives and economic rebasing, impacting capital placements and procedure growth.
Thank you, everyone, for standing by, and welcome to the Intuitive second-quarter 2024 earnings release. (Operator Instructions) As a reminder, today's call is being recorded. I will now turn the call over to your host, Head of Investor Relations, Brian King. Please go ahead.
Good afternoon, and welcome to Intuitive second-quarter earnings conference call. With me today, we have Gary Guthart, our CEO; Dave Rosa, our President; and Jamie Samath, our CFO.
Before we begin, I would like to inform you that comments mentioned on today's call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in our Securities and Exchange Commission filings, including our most recent Form 10-K for the fiscal year ended December 31, 2023, and subsequent filings.
Our SEC filings can be found through our website or at the SEC's website
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |